NAVLE Primates

Primate Rubeola Study Guide

📅 March 28, 2026 ⏱ 20 min read

Rubeola (measles) is a highly contagious viral disease caused by a morbillivirus of the family Paramyxoviridae.

Overview and Clinical Importance

Rubeola (measles) is a highly contagious viral disease caused by a morbillivirus of the family Paramyxoviridae. While primarily a human disease, rubeola poses a significant threat to nonhuman primates (NHPs) in captivity, laboratory, and zoo settings. Transmission occurs through human-to-primate contact, with humans serving as the natural reservoir. This is a critical zoonotic disease that can cause epizootic outbreaks with high morbidity and mortality in primate colonies.

Category	Susceptible Species	Disease Severity
Highly Susceptible	New World Species: Marmosets (Callitrichidae), Colobus monkeys	Severe disease with HIGH MORTALITY (can exceed 50-70%)
Moderately Susceptible	Old World Species: Rhesus macaques, Cynomolgus macaques, Baboons, African green monkeys	Mild to moderate disease; lower mortality; better immune response
Great Apes	Gorillas, Chimpanzees	Variable severity; significant morbidity possible

Etiology and Pathophysiology

Viral Characteristics

Causative Agent: Measles virus (MV), genus Morbillivirus, family Paramyxoviridae

Viral Structure: Enveloped, single-stranded negative-sense RNA virus with two key receptors:

CD150 (SLAM): Critical for viral entry and systemic dissemination; found on immune cells

Nectin-4: Found on epithelial cells; important for viral shedding

Transmission and Epidemiology

Route of Transmission: Highly contagious via airborne transmission through respiratory droplets and aerosols

Reservoir: Humans are the natural reservoir; NHPs acquire infection through contact with infected humans or imported infected animals

Incubation Period: Typically 10-14 days from exposure to onset of symptoms

Occurrence: Rare in wild populations; common in laboratory and zoo settings with human contact

NAVLE TipHumans are ALWAYS the source of measles infection in captive primates. If you see a measles outbreak in a primate colony on the exam, look for recent human exposure (new staff, visitors, or imported animals from endemic areas). Remember: No human contact = No measles risk.

Complication	Characteristics	Clinical Significance
Giant Cell Pneumonia	Interstitial pneumonitis with multinucleated giant cells containing viral inclusions	Most common cause of death in young primates; pathognomonic for measles
Secondary Bacterial Pneumonia	Due to immunosuppression; multiple bacterial species	Major cause of mortality; requires aggressive antibiotic therapy
Bacterial Enteritis	Severe diarrhea, especially in New World species	Rapid dehydration and death if untreated
Encephalitis	CNS inflammation; can occur acutely or delayed	Neurological deficits, seizures; macaques can develop subacute sclerosing panencephalitis years later
Rhinitis	Nasal discharge, congestion	Common early sign; facilitates viral shedding

Species Susceptibility

Measles virus naturally infects multiple primate species, but susceptibility and disease severity vary significantly between Old World and New World species.

Test Type	Method/Sample	Notes
RT-PCR	Respiratory secretions, urine, blood; highly sensitive and specific	Gold standard for acute diagnosis; detects viral RNA
Serology (IgM/IgG)	Serum; IgM appears 3-4 days after rash onset	IgM confirms acute infection; IgG indicates past infection or immunity
Viral Culture	Nasopharyngeal swab, urine, blood	Time-consuming; not commonly used; requires BSL-2 facility
Histopathology	Tissue biopsy or necropsy samples	Giant cells with inclusions are diagnostic; immunohistochemistry can confirm viral antigens
CBC	Blood sample	Leukopenia, lymphopenia, thrombocytopenia common

Clinical Signs and Presentation

Clinical illness in NHPs ranges from asymptomatic to rapidly fatal. The disease progresses through characteristic stages similar to human measles.

Prodromal Stage (2-3 days)

High Fever: Often exceeding 40.5°C (105°F)

The Three C's: Coryza (nasal discharge), Keratoconjunctivitis (red, watery eyes), Dry cough

Systemic Signs: Malaise, anorexia, lethargy

Lymphoid Changes: Generalized lymphadenopathy, splenomegaly

Pathognomonic Sign: Koplik spots - small white spots with red halos on buccal mucosa (appear 24-48 hours before rash)

Exanthematous Stage (Days 3-5)

Characteristic Rash: Maculopapular, erythematous rash that:

Appears first on the face and head (especially forehead)

Spreads cephalocaudally (head to tail) to neck, trunk, and extremities

Becomes confluent and deep reddish-purple in color

Associated with skin edema in late stages

Distribution: Non-pruritic rash on face, chest, and lower body portions

Fever Spike: Temperature may spike to greater than 104°F when rash appears

Recovery Stage (Days 7-10)

Resolution: Fever decreases, rash fades in same top-down sequence

Desquamation: Fine, powdery skin sloughing (can be extensive, resembling burn victims)

Immunity: Successful antibody production provides lifelong immunity

Species-Specific Clinical Features

New World Monkeys (Marmosets): Severe gastroenteritis, diarrhea, rapid progression to death

Old World Monkeys (Macaques): Swelling of footpads, conjunctivitis, pneumonia predominate

Treatment Category	Management Strategy
Supportive Care	Fluid Therapy: IV or SC fluids to maintain hydration (critical in animals with diarrhea) Nutritional Support: Assisted feeding, high-calorie supplements for anorexic animals Oxygen Therapy: For animals with pneumonia and respiratory distress
Secondary Infection Prevention	Broad-Spectrum Antibiotics: To prevent/treat secondary bacterial pneumonia and enteritis Examples: Enrofloxacin, cephalosporins, or combination therapy
Immunoglobulin (Post-Exposure)	Human Gamma-Globulin: May be used in event of colony outbreak for exposed but not yet symptomatic animals Not commonly available or practical for large outbreaks
Isolation and Quarantine	Immediately isolate all affected animals until resolution of clinical signs Institute 90-day quarantine for all new captive primates Restrict human access to affected colonies

Complications

Measles virus is highly immunosuppressive, causing dysfunction of both humoral and cell-mediated immunity that may last weeks to months, predisposing to secondary infections.

NAVLE TipGiant cell pneumonia with intranuclear and intracytoplasmic inclusion bodies is PATHOGNOMONIC for measles in primates. If you see 'multinucleated giant cells' in lung tissue from a dead primate with a recent rash, think MEASLES first. This lesion is also called Hecht's disease or Hecht's giant cell pneumonia.

Vaccine Type	Recommended For	Protocol
Human Measles Vaccine (MMR)	Old World monkeys greater than 6 months old (macaques, baboons)	Two doses, 3 months apart; effective but more expensive
Canine Distemper-Measles Vaccine	Old World monkeys (rhesus, cynomolgus macaques) - PREFERRED	Two doses, 3 months apart; equally or more effective than human vaccine; less expensive; half-dose reduces cost by 50 percent
Modified Live Vaccine	NOT RECOMMENDED for marmosets or New World species	Can CAUSE disease in highly susceptible species

Pathology and Pathogenesis

Microscopic Findings

Epithelial Giant Cells: Multinucleated cells with viral inclusions in respiratory epithelium

Cowdry Type A Inclusions: Single large intranuclear inclusion bodies

Warthin-Finkeldey Giant Cells: Reticuloendothelial giant cells found in lymphoid tissue (lymph nodes, spleen)

Skin Pathology: Infection of dermal myeloid and lymphoid cells precedes epidermal spread to keratinocytes; hyperemia and edema cause characteristic rash appearance

Viral Pathogenesis

Entry: Virus enters via respiratory tract, infects respiratory epithelium and immune cells

Lymphoid Spread: Virus spreads to local lymph nodes; infects CD150-positive T cells and macrophages

Viremia: Infected immune cells disseminate virus systemically via bloodstream

Tissue Invasion: Virus infects epithelial cells (nectin-4 receptor) in skin, respiratory tract, GI tract

Immune Clearance: CD8-positive T cells and antibodies clear infected cells; coincides with rash appearance

Diagnosis

Clinical Diagnosis

Measles is primarily a clinical diagnosis based on:

Recent human contact or exposure history

Characteristic prodrome (fever, coryza, cough, conjunctivitis)

Koplik spots (pathognomonic but not always present)

Maculopapular rash spreading cephalocaudally

Laboratory Diagnosis

Exam Focus: For the NAVLE, remember that Koplik spots appearing 24-48 hours BEFORE the rash are pathognomonic for measles but are NOT always present. Don't rule out measles just because Koplik spots are absent. The characteristic cephalocaudal rash progression + fever + recent human exposure = measles until proven otherwise.

Treatment and Management

No specific antiviral treatment exists for measles in nonhuman primates. Management is supportive and symptomatic.

NAVLE TipThere is NO specific antiviral for measles in primates. Do NOT use modified live measles vaccine in marmosets - it can cause DISEASE in this highly susceptible species. The key to managing measles outbreaks is PREVENTION through vaccination of both animals and human personnel.

Prevention and Vaccination

Prevention is critical given the lack of specific treatment and high mortality in susceptible species.

Biosecurity Measures

Personnel Vaccination: Immunization of ALL personnel in contact with NHPs (MMR vaccine)

Quarantine Protocols: 90-day quarantine for all new captive primates introduced to facility

Access Restrictions: Do not allow NHPs (especially marmosets) to interact with humans who have measles or are unvaccinated; no child contact with marmosets

Personal Protective Equipment: Use of face masks and PPE when working with NHPs

Environmental Disinfection: Adequately disinfect areas where potentially infected individuals/NHPs are present

Vaccination of Nonhuman Primates

Vaccination Schedule and Efficacy

Age of Vaccination: Infant rhesus monkeys and macaques over 6 months old

Primary Series: Two doses administered 3 months apart

Efficacy: Both human and canine distemper-measles vaccines provide protective immunity

Cross-Protection: Measles vaccination provides partial protection against canine distemper virus in some species

Public Health and Zoonotic Considerations

Reverse Zoonosis: Measles is transmitted FROM humans TO primates (anthroponosis)

Primate-to-Human Transmission: Rare but documented cases of humans contracting measles from infected macaques during large outbreaks

Facility Impact: Outbreaks can devastate research colonies, zoos, and sanctuaries with economic losses and research disruption

Reportable Disease: Measles outbreaks in captive primate populations should be reported to appropriate authorities

Exam Focus: On the NAVLE, if you see a question about a measles outbreak in a primate facility, the FIRST biosecurity measure should be ensuring ALL human personnel are vaccinated against measles. The second measure is immediate isolation of affected animals and restricted access. Remember: humans are ALWAYS the source!

Practice NAVLE Questions

Test your knowledge with 10,000+ exam-style questions, detailed explanations, and timed exams.

Start Your Free Trial →